PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), announced the achievement of a preclinical development milestone in ...

Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam is making a $250 million investment in its Massachusetts manufacturing facility. The investment comes as the company begins to expand beyond rare disease treatments into more common conditions ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

Alnylam (ALNY) announced the planned expansion of its manufacturing facility in Norton, Massachusetts. The company is preparing to invest $250M to ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...